Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma.
Martin Filipits(University of Vienna), Robert Pirker(Medical University of Vienna), H. Kaufmann, H Gisslinger, H. Huber(Munich University of Applied Sciences), Robert Königsberg, H. Ludwig, Johannes Drach(Vienna General Hospital), J Ackermann, Thomas Stranzl, Gudrun Pohl, J. C. Schuster(Wilhelminen Hospital)
PubMed
September 1, 1999
Cited by 44
Related Papers
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
|The Lancet Oncology|2011|574
Summary of constitutional data on the Aluminum-Carbon-Titanium system
|Journal of Phase Equilibria|1994|441